Previously, loss-of-function mutations in BRCA1 and FBXW7, an E3 ubiquitin ligase that marks cyclin E for proteolytic destruction [15], were associated with clinical benefit in patients with HNSCC or SCCA [12]. This evidence concerns the gene CCNE1 and head and neck squamous cell carcinoma.